Reference is made to the stock exchange notice by Hofseth Biocare ASA (the "Company") published on 24 July 2019, regarding a contemplated private placement of new shares for gross proceeds of up to approximately NOK 118 million (the "Private Placement").
The Company has received applications for shares that fully covers the offer size at the offer price. To facilitate pending applications that has not yet been received from international investors due to vacation time and time differences, the Board of Directors has decided to extend the application period until Monday 29 July 2019 at 08:00 CEST.
The Board of Directors will decide on the allocation of the shares on Monday afternoon.
For further information, please contact:
Roger Hofseth, CEO of Hofseth BioCare ASA
Phone: +47 951 47 941
E-mail: rh@hofseth-as.no
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act